Observational studyBreast cancer (Tokyo, Japan)2026
Real-world outcomes of palbociclib plus endocrine therapy in elderly patients with HR+/HER2- advanced breast cancer in Japan: a subgroup analysis of the P-BRIDGE study by age group.
Observational study in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundPalbociclib (PAL), a cyclin-dependent kinase 4/6 inhibitor, plus endocrine therapy (ET) is recommended as first-line (1L) treatment for hormone receptor-positive (HR+)/ human epidermal growth factor 2 negative (HER2-) advanced breast cancer (ABC). Despite broad use in real-world clinical settings, few studies have evaluated its effectiveness in elderly patients in Japan.
methodsThe multicenter, observational P-BRIDGE study included HR+/HER2- ABC patients (N = 693) who initiated PAL + ET as 1L or second-line treatment during 2017–2020 in Japan. Treatment outcomes and patterns were evaluated by age category (< 65; ≥ 65 to < 75; ≥ 75 years).
resultsAmong patients treated with 1L PAL + ET (N = 426), 266, 118, and 42 patients were aged < 65, ≥ 65 to < 75, and ≥ 75 years, respectively. Patients aged ≥ 75 years were less likely to initiate PAL at 125 mg (64.3%) than patients aged < 65 (95.5%) and ≥ 65 to < 75 (88.1%) years. More patients aged ≥ 75 years discontinued PAL due to adverse events than other age groups. Median real-world progression-free survival (95% CI) was 24.5 months (18.2–30,4), 25.7 months (16.8–36.7), and 45.4 months (20.4–52.4), in the < 65, ≥ 65 to < 75, and ≥ 75-year age groups, respectively. Corresponding median overall survival was 68.2 months (65.0-not reached [NR]), NR (56.3-NR), and 68.0 months (45.8-NR), respectively.
conclusionsThe effectiveness of PAL + ET in elderly patients in the real-world setting in Japan appears comparable to other age groups. These findings support PAL + ET as a viable treatment option for all patients, including the elderly, while highlighting the need for close monitoring and individualized treatment strategies, especially in older patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.